£495.00

The 2013-2018 Outlook for Calcium Channel Blocker Vasodilator Pharmaceuticals in India

Price data last checked 24 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£495 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey
↓ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 67 days · 67 data points (no recent data)

Historical
Generating forecast…
£495.00 £470.25 £480.15 £490.05 £499.95 £509.85 £519.75 10 June 2026 26 June 2026 13 July 2026 29 July 2026 15 August 2026

Price Distribution

Price distribution over 67 days • 1 price levels

Days at Price
67 days 0 17 34 50 67 £495 Days at Price

Price Analysis

Most common price: £495 (67 days, 100.0%)

Price range: £495 - £495

Price levels: 1 different prices over 67 days

Description

This econometric study covers the latent demand outlook for calcium channel blocker vasodilator pharmaceuticals across the states, union territories and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 5,100 cities in India. For each city in question, the percent share the city is of it's state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-a-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state or union territory and city, latent demand estimates are created for calcium channel blocker vasodilator pharmaceuticals. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the cities in India). This study gives, however, my estimates for the latent demand, or the P.I.E., for calcium channel blocker vasodilator pharmaceuticals in India. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of India. For each state or union territory, I also show my estimates of how the P.I.E. grows over time. In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on strategic planning at graduate schools of business.

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
09 January 2013
Listed Since
24 January 2013

Similar Products You Might Like

The 2016-2021 Outlook for Calcium Channel Blocker Vasodilator Pharmaceuticals in Japan
99% match

The 2016-2021 Outlook for Calcium Channel Blocker Vasodilator Pharmaceuticals in Japan

£595.00 23 Aug 2026
The 2016-2021 Outlook for Calcium Channel Blocker Vasodilator Pharmaceuticals in Greater China
99% match

The 2016-2021 Outlook for Calcium Channel Blocker Vasodilator Pharmaceuticals in Greater China

£595.00 10 Jul 2026
The 2021-2026 World Outlook for Calcium Channel Blocker Vasodilator Pharmaceuticals
98% match

The 2021-2026 World Outlook for Calcium Channel Blocker Vasodilator Pharmaceuticals

£795.00 15 Aug 2026
The 2013-2018 Outlook for Coronary Vasodilator Pharmaceuticals in India
98% match

The 2013-2018 Outlook for Coronary Vasodilator Pharmaceuticals in India

£495.00 12 Aug 2026
The 2013-2018 Outlook for Peripheral Vasodilator Pharmaceuticals in India
97% match

The 2013-2018 Outlook for Peripheral Vasodilator Pharmaceuticals in India

£495.00 14 Aug 2026
The 2016-2021 Outlook for Coronary Vasodilator Pharmaceuticals in Greater China
97% match

The 2016-2021 Outlook for Coronary Vasodilator Pharmaceuticals in Greater China

£595.00 22 Aug 2026
The 2016-2021 Outlook for Coronary Vasodilator Pharmaceuticals in Japan
97% match

The 2016-2021 Outlook for Coronary Vasodilator Pharmaceuticals in Japan

£595.00 26 Aug 2026
The 2021-2026 World Outlook for Coronary Vasodilator Pharmaceuticals
97% match

The 2021-2026 World Outlook for Coronary Vasodilator Pharmaceuticals

£795.00 16 Jul 2026
The 2023-2028 Outlook for Renin-Angiotensin System-Blocking Cardiovascular Drugs in the United States
96% match

The 2023-2028 Outlook for Renin-Angiotensin System-Blocking Cardiovascular Drugs in the United States

£520.00 03 Sep 2026
The 2023-2028 Outlook for Renin-Angiotensin System-Blocking Cardiovascular Drugs in India
96% match

The 2023-2028 Outlook for Renin-Angiotensin System-Blocking Cardiovascular Drugs in India

£515.00 25 Aug 2026
The 2013-2018 Outlook for Cardiovascular Catheters in North America & the Caribbean
96% match

The 2013-2018 Outlook for Cardiovascular Catheters in North America & the Caribbean

£325.00 25 Aug 2026
The 2016-2021 Outlook for Ace Inhibitor Vasodilator Pharmaceuticals in Japan
96% match

The 2016-2021 Outlook for Ace Inhibitor Vasodilator Pharmaceuticals in Japan

£595.00 03 Sep 2026
The 2016-2021 Outlook for Peripheral Vasodilator Pharmaceuticals in the United States
96% match

The 2016-2021 Outlook for Peripheral Vasodilator Pharmaceuticals in the United States

£595.00 10 Jul 2026
The 2013-2018 Outlook for Anti-Arrhythmic Vasodilator Pharmaceuticals in India
96% match

The 2013-2018 Outlook for Anti-Arrhythmic Vasodilator Pharmaceuticals in India

£495.00 13 Aug 2026
The 2023-2028 Outlook for Renin-Angiotensin System-Blocking Cardiovascular Drugs in China
96% match

The 2023-2028 Outlook for Renin-Angiotensin System-Blocking Cardiovascular Drugs in China

£495.00 15 Jul 2026
The 2021-2026 World Outlook for Ace Inhibitor Vasodilator Pharmaceuticals
96% match

The 2021-2026 World Outlook for Ace Inhibitor Vasodilator Pharmaceuticals

£795.00 11 Jul 2026
The 2023-2028 World Outlook for Web-Based Cardiovascular Information Systems
96% match

The 2023-2028 World Outlook for Web-Based Cardiovascular Information Systems

£795.00 19 Aug 2026
The 2023-2028 Outlook for Renin-Angiotensin System-Blocking Cardiovascular Drugs for US Zip Codes
96% match

The 2023-2028 Outlook for Renin-Angiotensin System-Blocking Cardiovascular Drugs for US Zip Codes

£490.00 27 Aug 2026
The 2016-2021 Outlook for Peripheral Vasodilator Pharmaceuticals in Japan
96% match

The 2016-2021 Outlook for Peripheral Vasodilator Pharmaceuticals in Japan

£595.00 03 Sep 2026
The 2023-2028 Outlook for Renin-Angiotensin System-Blocking Cardiovascular Drugs in Japan
96% match

The 2023-2028 Outlook for Renin-Angiotensin System-Blocking Cardiovascular Drugs in Japan

£495.00 25 Aug 2026
The 2013-2018 Outlook for Anti-Hypertensive Drugs in India
96% match

The 2013-2018 Outlook for Anti-Hypertensive Drugs in India

£495.00 15 Aug 2026
The 2023-2028 World Outlook for Cardiovascular Information Systems
96% match

The 2023-2028 World Outlook for Cardiovascular Information Systems

£795.00 15 Aug 2026
The 2013-2018 Outlook for Blood Pressure Transducers in India
96% match

The 2013-2018 Outlook for Blood Pressure Transducers in India

£495.00 13 Aug 2026
The 2013-2018 Outlook for Percutaneous Transluminal Coronary Angioplasty (PTCA) Products in India
96% match

The 2013-2018 Outlook for Percutaneous Transluminal Coronary Angioplasty (PTCA) Products in India

£495.00 25 Aug 2026